Medtronic wins FDA approval for its adjustable spine-pain implant. This latest version can sense nerve signals and automatically change the intensity.
Medtronic said the U.S. Food and Drug Administration has approved a new spinal-cord implant that relieves chronic pain, a bid to expand into a patient population that relies heavily on medications like opioids. The new device works by delivering an electrical pulse to the spinal cord, interrupting pain signals before they reach the brain in patients suffering from back, cervical and nerve damage.
The use of spinal-cord stimulators has increased significantly over the past decade, although their use has been constrained by limited awareness from patients and primary-care doctors, said Justin Davanzo, a neurosurgeon with Allegheny Health in Pennsylvania. Some patients report that if they bend or move a certain way, they feel “a zap or a zing down their back,” Davanzo said. Next-generation devices — like the ones developed by Saluda and Medtronic — could improve patient comfort, he said.
United Kingdom Latest News, United Kingdom Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Medtronic wins FDA approval for adjustable spine-pain implantMedtronic said that the FDA approved its new spinal implant, which delivers a variable electrical pulse to interrupt pain signals before they reach the brain.
Read more »
Experts Call for Revoking FDA Approval of Opioid TestA group of experts has written a letter to the FDA commissioner, urging the agency to revoke its approval of a test called AvertD, which is meant to detect genetic markers associated with opioid use disorder. The experts argue that the test doesn't work and may contribute to overprescribing and an increased incidence of opioid use disorder.
Read more »
Many cancer drugs remain unproven years after FDA's accelerated approval, study findsThe FDA's accelerated approval program is meant to give patients early access to promising drugs, but a new study found most cancer drugs do not demonstrate benefits within five years.
Read more »
Study Finds Limited Clinical Benefit for Cancer Drugs Approved Under FDA's Accelerated Approval PathwayA new study reveals that less than half of the cancer drugs approved under the FDA's accelerated approval pathway have been shown to improve overall survival or quality of life, despite being on the market for more than 5 years.
Read more »
Most Cancer Drugs Granted Accelerated Approval by FDA Do Not Show Benefits Within Five YearsA new study reveals that the majority of cancer drugs granted accelerated approval by the FDA do not demonstrate benefits within five years.
Read more »
FDA Expands Enhertu Indication to HER2-Positive Solid TumorsThe move from the FDA marks the first tumor-agnostic approval of a HER2-directed therapy and antibody drug conjugate.
Read more »